Skip to Content

Align Technology Inc ALGN

Morningstar Rating
$220.45 −5.60 (2.48%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Align Earnings: Not a Lot to Smile About as Volume Wins Not Enough to Offset Sluggish Pricing

Narrow-moat Align Technology reported lower-than-expected second-quarter results. Total sales of $1.028 billion were up 2.6% year over year, narrowly missing last quarter’s guidance of $1.03 billion-$1.05 billion, as strong systems and services performance was partially offset by weaker clear aligners business. Systems and services continues to benefit from the iTero Lumina launch from early 2024, but we expect tailwinds to be curtailed for the second half of the year as offices wait to upgrade their scanner until Lumina’s restorative capabilities fully roll out in 2025. Clear aligners posted a 0.1% sales decline during the quarter despite a moderately growing volume due to a sluggish average selling price, or ASP. Unfavorable product mix from an increasing utilization of the Invisalign Doctor Subscription Program, difficult foreign exchange headwinds, and discounts all led to lower-than-anticipated ASP. Management lowered full-year sales growth guidance to 4%-6% from the previous 6%-8% after citing that low ASP is likely to continue posing challenges for the remainder of the year. After digesting July 25’s results and trimming our near-term assumptions, we lower our fair value estimate to $300 per share from $320.

Price vs Fair Value

ALGN is trading at a 567% premium.
Price
$220.45
Fair Value
$724.00
Uncertainty
High
1-Star Price
$557.00
5-Star Price
$981.00
Economic Moat
Thtvfyc
Capital Allocation
Qbpjcpffl

Bulls Say, Bears Say

Bulls

Invisalign is likely to win over new doctors and patients as adoption of clear aligners increases and chips away at wire and bracket market share.

Bears

Increasing competition in the clear aligner market could erode Invisalign’s market share over the long term.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALGN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$226.05
Day Range
$218.85226.41
52-Week Range
$176.34413.20
Bid/Ask
$219.36 / $220.78
Market Cap
$16.60 Bil
Volume/Avg
1.2 Mil / 805,433

Key Statistics

Price/Earnings (Normalized)
24.71
Price/Sales
4.24
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.65%

Company Profile

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients’ teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
21,670

Competitors

Valuation

Metric
ALGN
XRAY
STMN
Price/Earnings (Normalized)
24.7114.2039.38
Price/Book Value
4.421.689.85
Price/Sales
4.241.417.50
Price/Cash Flow
31.9711.6331.26
Price/Earnings
ALGN
XRAY
STMN

Financial Strength

Metric
ALGN
XRAY
STMN
Quick Ratio
1.020.711.34
Current Ratio
1.231.431.95
Interest Coverage
−0.4519.50
Quick Ratio
ALGN
XRAY
STMN

Profitability

Metric
ALGN
XRAY
STMN
Return on Assets (Normalized)
11.78%5.31%13.05%
Return on Equity (Normalized)
19.68%11.38%23.67%
Return on Invested Capital (Normalized)
18.66%8.02%18.17%
Return on Assets
ALGN
XRAY
STMN
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
YxpbmtbsDxhkjpn$183.1 Bil
Stryker Corp
SYK
KwdbbntygjMkdn$126.3 Bil
Boston Scientific Corp
BSX
ZwdsdyggnXxwsqj$110.1 Bil
Medtronic PLC
MDT
LsgmcsmxCdkvyzn$100.9 Bil
Edwards Lifesciences Corp
EW
XncqwqqhdShrdl$37.6 Bil
DexCom Inc
DXCM
CjhnfxfnqGvc$25.6 Bil
Koninklijke Philips NV ADR
PHG
SljcpwgzZtctpf$24.1 Bil
Steris PLC
STE
LvstrvkfyQsywrb$23.0 Bil
Zimmer Biomet Holdings Inc
ZBH
NvmsjxwnqKsz$22.9 Bil

Sponsor Center